Study of the immunological efficacy of adding subcutaneous interleukin-2 (IL-2) to an optimized antiretroviral regimen in HIV-1-infected subjects experiencing therapeutic failure on an ongoing antiretroviral combination with a CD4 cell count less than or equal to 200/mm3 ANRS 123 trial.

Trial Profile

Study of the immunological efficacy of adding subcutaneous interleukin-2 (IL-2) to an optimized antiretroviral regimen in HIV-1-infected subjects experiencing therapeutic failure on an ongoing antiretroviral combination with a CD4 cell count less than or equal to 200/mm3 ANRS 123 trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2015

At a glance

  • Drugs Interleukin-2 (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ETOILE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jul 2009 Primary endpoint 'CD4+ cell count' has not been met.
    • 17 Jul 2009 Results have been reported in AIDS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top